Ipamorelin 5 mg
$70.00
British Dragon Ipamorelin 5 mg – Selective Growth Hormone Secretagogue
British Dragon Ipamorelin 5 mg is a third-generation growth hormone-releasing peptide (GHRP) known for its selectivity and minimal impact on cortisol and prolactin. Each 2 mL vial contains 5 mg of lyophilized Ipamorelin, designed for reconstitution in research settings investigating growth hormone release mechanisms.
Unlike earlier GHRP compounds, Ipamorelin demonstrates high specificity for the ghrelin receptor (GHS-R1a) with reduced side effect profile in animal models. For researchers studying lean mass, recovery, or metabolic function, this peptide offers a distinct mechanism compared to synthetic GH. Explore similar research compounds like Sermorelin 5 mg or Tesamorelin 5 mg.
What Makes British Dragon Ipamorelin Unique?
Ipamorelin's primary distinction lies in its selectivity. While GHRP-2 and GHRP-6 can elevate cortisol and prolactin in some research models, Ipamorelin demonstrates minimal effect on these hormones while maintaining robust GH release. This makes it a preferred tool for studies requiring isolated GH pathway activation.
For performance-focused research, Ipamorelin is often studied in combination with growth hormone-releasing hormone (GHRH) analogs like Sermorelin to evaluate synergistic effects on GH pulsatility. The 5 mg dosage provides flexibility for both acute and extended research protocols.
Benefits of British Dragon Ipamorelin for Research
- ✔ Selective GHS-R1a agonist with minimal off-target effects
- ✔ Low impact on cortisol and prolactin in animal models
- ✔ 5 mg lyophilized powder for reconstitution flexibility
- ✔ Suitable for subcutaneous administration research
- ✔ Can be stacked with GHRH analogs for pulsatile release studies
British Dragon Ipamorelin 5 mg is intended for laboratory research only. Not for human consumption or clinical use.
External research on Ipamorelin's mechanisms can be explored via PubMed for peer-reviewed studies.